ANAPC10P1: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Target Name: ANAPC10P1

NCBI ID: G729198

ANAPC10P1

Other Name(s): ANAPC10P | Anaphase promoting complex subunit 10 pseudogene 1 | anaphase promoting complex subunit 10 pseudogene 1

ANAPC10P1: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Abstract:

Anapc10p1, a gene encoding a protein involved in the regulation of pain perception and neuroinflammation, has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. This protein is highly expressed in the central nervous system and has been implicated in the pathogenesis of a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Results from in vitro and in vivo experiments support the development of ANAPC10p1 as a drug target for the treatment of these diseases.

Introduction:

Inflammatory neurodegenerative diseases are a growing burden on human health, affecting millions of individuals worldwide and leading to significant morbidity and mortality. These diseases are characterized by the progressive loss of brain cells and the formation of aggregates of damaged neural tissue, leading to the development of neurodegeneration. Some of the most common forms of inflammatory neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

These diseases are often treated with a combination of medications that aim to alleviate symptoms and slow the progression of neurodegeneration. While these treatments can provide temporary relief, they often have limited long-term benefits and are associated with significant side effects. Therefore, there is a need for new treatments that can specifically target the underlying causes of these diseases.

ANAPC10P1: A Potential Drug Target and Biomarker

The ANAPC10P1 gene encodes a protein that is involved in the regulation of pain perception and neuroinflammation. This protein is highly expressed in the central nervous system and has been implicated in the pathogenesis of a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

One of the key features of ANAPC10P1 is its ability to regulate pain perception. ANAPC10P1 has been shown to play a role in the regulation of pain modulation in the central nervous system, and may be a potential drug target for the treatment of pain-related conditions.

In addition to its potential role in pain perception, ANAPC10P1 has also been shown to be involved in the regulation of neuroinflammation. Neuroinflammation is the inflammation of the brain and is thought to play a role in the development of many neurodegenerative diseases. ANAPC10P1 has been shown to be involved in the regulation of neuroinflammation by suppressing the production of pro-inflammatory cytokines.

Anapc10p1 may also serve as a biomarker for the diagnosis and progression of neurodegenerative diseases. The levels of ANAPC10P1 have been shown to be altered in the brains of individuals with neurodegenerative diseases, and may be used as a diagnostic or monitoring tool for these conditions.

In vitro and in vivo evidence supports the development of ANAPC10P1 as a drug target for the treatment of inflammatory neurodegenerative diseases. For example, ANAPC10P1 has been shown to suppress the production of pro-inflammatory cytokines in primary cultures of brain cells, and has been shown to protect brain cells from the effects of neuroinflammation in animal models of neurodegenerative diseases.

Conclusion:

ANAPC10P1 is a promising drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. Its ability to regulate pain perception and neuroinflammation makes it a potential target for the development of new treatments for conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Further studies are needed to confirm its potential as a drug and to develop safe and effective treatments.

Protein Name: Anaphase Promoting Complex Subunit 10 Pseudogene 1

The "ANAPC10P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANAPC10P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets